Therefore, we conducted a phase I study to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of afatinib for phase II trial in elderly patients aged 75 or older with NSCLC harboring EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.